Product Description
AI Product Description
*The following content is generated by AI and is for reference only.
Icotinib, often designated by its internal code N-2 in early research phases, is a potent and selective small-molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. With the molecular formula C24H25ClFN3O2S and CAS Registry Number 860179-84-0, this compound represents a significant advancement in targeted cancer therapy, particularly for non-small cell lung cancer (NSCLC). Structurally, Icotinib features a quinazoline core substituted with specific functional groups that enable high-affinity binding to the ATP-binding pocket of EGFR, effectively blocking downstream signaling pathways essential for tumor cell proliferation and survival.
Unlike earlier generation inhibitors, Icotinib demonstrates superior selectivity against wild-type EGFR while maintaining strong activity against common sensitizing mutations such as exon 19 deletions and L858R point mutations. This pharmacological profile minimizes off-target effects, thereby reducing toxicity compared to non-selective agents. The drug has gained widespread clinical approval in China, where it serves as a first-line treatment option for patients with locally advanced or metastatic NSCLC harboring specific EGFR mutations. Its oral bioavailability allows for convenient administration in outpatient settings, significantly improving patient quality of life during long-term therapy.
Beyond clinical applications, Icotinib plays a crucial role in pharmaceutical research as a reference standard for studying EGFR resistance mechanisms and developing next-generation inhibitors. Scientists utilize this compound to validate new drug candidates and explore combination therapies aimed at overcoming acquired resistance. As precision medicine continues to evolve, Icotinib remains a cornerstone agent in the management of EGFR-driven malignancies, offering hope to patients worldwide through its efficacy and favorable safety profile. Ongoing studies continue to investigate its potential in broader oncological indications and novel delivery systems to further enhance therapeutic outcomes.